Efficacy and safety of ocrelizumab vs interferon beta-1a in participants of African descent with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies
Publication date: Available online 7 May 2021Source: Multiple Sclerosis and Related DisordersAuthor(s): Bruce A.C. Cree, Ashish Pradhan, Jinglan Pei, Mitzi J. Williams, OPERA I and OPERA II clinical investigators (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - May 8, 2021 Category: Neurology Source Type: research
Real-world propensity score comparison of treatment effectiveness of peginterferon beta-1a vs. subcutaneous interferon beta-1a, glatiramer acetate, and teriflunomide in patients with relapsing-remitting multiple sclerosis
Publication date: June 2021Source: Multiple Sclerosis and Related Disorders, Volume 51Author(s): Anthony T Reder, Nancy Arndt, Cortnee Roman, Caroline Geremakis, Jason P Mendoza, Ray Su, Charles Makin, Robin L Avila, Megan C Vignos (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - April 19, 2021 Category: Neurology Source Type: research
Impact of adherence to disease-modifying therapies on employment among veterans with multiple sclerosis
CONCLUSION: In this study veterans who adhered to their DMTs were 2.4 times more likely to be in paid-employment compared to non- or poorly-adherent patients. The clinical significance of this study is to encourage MS patients to adhere to their DMTs as a motivating factor of being in paid-employment.Implications for rehabilitationWhat is known about this subject? In the setting of a randomized controlled trial adherence rates reported for different injectable DMTs vary from 79-85% for once a week interferon beta-1a (IM IFNb-1a) to 49-78% for other injectable DMTs.•What are the new findings and/or impact on clinical prac...
Source: Disability and Rehabilitation - April 7, 2021 Category: Rehabilitation Authors: Meheroz H Rabadi Kimberly Just Chao Xu Source Type: research
Impact of adherence to disease-modifying therapies on employment among veterans with multiple sclerosis
CONCLUSION: In this study veterans who adhered to their DMTs were 2.4 times more likely to be in paid-employment compared to non- or poorly-adherent patients. The clinical significance of this study is to encourage MS patients to adhere to their DMTs as a motivating factor of being in paid-employment.Implications for rehabilitationWhat is known about this subject? In the setting of a randomized controlled trial adherence rates reported for different injectable DMTs vary from 79-85% for once a week interferon beta-1a (IM IFNb-1a) to 49-78% for other injectable DMTs.•What are the new findings and/or impact on clinical prac...
Source: Disability and Rehabilitation - April 7, 2021 Category: Rehabilitation Authors: Meheroz H Rabadi Kimberly Just Chao Xu Source Type: research
Cost Effectiveness and Budget Impact of Siponimod Compared to Interferon Beta-1a in the Treatment of Adult Patients with Secondary Progressive Multiple Sclerosis with Active Disease in Switzerland
ConclusionsIn the base-case analysis, we found that siponimod may be cost effective for treating Swiss adult patients with SPMS with active disease. The results of the cost-effectiveness analyses are valid under the assumption that the efficacy of siponimod and the comparators on disability progression for the overall SPMS population would be the same in the active SPMS population.Clinical Trial IdentifierNCT01665144. This economic evaluation was based on the EXPAND trial. (Source: PharmacoEconomics)
Source: PharmacoEconomics - April 1, 2021 Category: Health Management Source Type: research
COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies
ConclusionsComorbidities, obesity, and Black/African ancestry, but not age, were associated with a higher risk of SARS-CoV-2 infection in PwMS. Interferons and glatiramer acetate were associated with a reduced COVID-19 risk, whereas anti-CD20 therapies were associated with an increased risk, within the treated MS cohort. COVID-19 safety reports for patients receiving Biogen MS therapies were consistent with the Explorys database and MS literature, illustrating the replicability and power of this approach. (Source: CNS Drugs)
Source: CNS Drugs - March 20, 2021 Category: Neurology Source Type: research
Evolution of Brain Volume Loss Rates in Early Stages of Multiple Sclerosis
Conclusions
The rate of BVL is relatively stable throughout the course of RRMS. The accelerated BVL is weakly associated with concurrent higher disease activity, and timely escalation to high-efficacy immunotherapy helps decrease the rate of BVL. (Source: Neurology Neuroimmunology and Neuroinflammation)
Source: Neurology Neuroimmunology and Neuroinflammation - March 16, 2021 Category: Neurology Authors: Uher, T., Krasensky, J., Malpas, C., Bergsland, N., Dwyer, M. G., Kubala Havrdova, E., Vaneckova, M., Horakova, D., Zivadinov, R., Kalincik, T. Tags: Volumetric MRI, Multiple sclerosis Article Source Type: research
Long-term fingolimod treatment in two pediatric patients with multiple sclerosis
AbstractData suggest that patients with pediatric-onset multiple sclerosis (POMS) should initiate treatment with a disease-modifying therapy early to slow progression. The PARADIGMS trial demonstrated that oral fingolimod reduced the annual rate of relapse by 82% compared with intramuscular interferon beta-1a in children with POMS. The PARADIGMS study had a follow-up of 2 years, but no data are available about the safety and efficacy of fingolimod for longer periods in children with POMS. Here we present two cases of children with POMS who achieved sustained clinical benefit from treatment with fingolimod for more than 2 y...
Source: Neurological Sciences - March 10, 2021 Category: Neurology Source Type: research
A randomized pharmacokinetic-pharmacodynamic evaluation of the potential biosimilar interferon beta-1a product, CinnoVex ®
. (Source: Expert Opinion on Biological Therapy)
Source: Expert Opinion on Biological Therapy - March 8, 2021 Category: Drugs & Pharmacology Authors: Mika Scheinin Zs ófia Lovró Inger-Helen Maadik Jaana Suopanki-Lalowski Seyed Hossein Seyedagha Morteza Azhdarzadeh Source Type: research
Drugs for Multiple Sclerosis
Date: March 22, 2021
Issue #:
1620Summary:
Most patients with multiple sclerosis (MS) present
with the relapsing-remitting form of the disease.
Pharmacologic treatment usually includes a
disease-modifying drug, corticosteroids for acute
exacerbations, and other drugs for managing
symptoms such as fatigue, depression, and pain.
Early use of disease-modifying therapy has improved
clinical outcomes. (Source: The Medical Letter)
Source: The Medical Letter - February 9, 2021 Category: Drugs & Pharmacology Authors: admin Tags: Alemtuzumab Aubagio Avonex Betaseron Cladribine Copaxone dimethyl fumarate diroximel Extavia Fingolimod Gilenya Glatect Glatiramer acetate Glatopa Interferon beta Kesimpta Lemtrada Mavenclad Mayzent mitoxantrone Mul Source Type: research
Plitidepsin: a repurposed drug for the treatment of COVID-19.
Abstract
Finding antivirals to reduce coronavirus disease 2019 (COVID-19) morbidity and mortality has been challenging. Large randomized clinical trials that aimed to test four repurposed drugs, hydroxychloroquine, lopinavir-ritonavir, interferon beta-1a, and remdesivir, have shown that these compounds lacked impact on the COVID-19 course. Although the Phase III COVID-19 vaccine trial results are encouraging, the search for effective COVID-19 therapeutics should not stop. Recently, plitidepsin (aplidin) demonstrated highly effective preclinical activity against severe acute respiratory syndrome coronavirus...
Source: Antimicrobial Agents and Chemotherapy - February 8, 2021 Category: Microbiology Authors: Martinez MA Tags: Antimicrob Agents Chemother Source Type: research
DORADA adherence study: full view into RebiSmart subdomains parameters in multiple sclerosis treatment.
CONCLUSION: These findings are in line with the potential benefits of RebiSmart to treatment adherence. They demonstrate an overall, very good perception of the device by patients and its individual functions.
PMID: 33538199 [PubMed - as supplied by publisher] (Source: Current Medical Research and Opinion)
Source: Current Medical Research and Opinion - February 6, 2021 Category: Research Tags: Curr Med Res Opin Source Type: research
MAGNIMS score predicts long-term clinical disease activity-free status and confirmed disability progression in patients treated with subcutaneous interferon beta-1a
Publication date: Available online 22 January 2021Source: Multiple Sclerosis and Related DisordersAuthor(s): Maria P. Sormani, Mark S. Freedman, Julie Aldridge, Kurt Marhardt, Ludwig Kappos, Nicola De Stefano (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - January 22, 2021 Category: Neurology Source Type: research
Correction to: Pegylated interferon beta-1a (Plegridy) Italian real-world experience: a Delphi analysis of injection-site reaction and flu-like symptom management
A Correction to this paper has been published:https://doi.org/10.1007/s10072-021-05083-8 (Source: Neurological Sciences)
Source: Neurological Sciences - January 22, 2021 Category: Neurology Source Type: research
